Monday, Dec 18, 2017
engineered enzymes for better healthcare

Enzolve_newborn_screeningNewborn babies are routinely screened for a number of genetically inherited conditions. These are usually defects of amino acid metabolism or other enzyme-dependent disorders. These deficiencies can cause severe mental retardation, liver, kidney or other organ failure and in many cases can lead to premature death. However, when detected early enough they can be adequately controlled to prevent symptomatic expression and severe disease. Thus early detection is vital to avoid potentially fatal consequences.

Worldwide over 130 million babies are born every year. Approximately 35 million of these babies are currently screened for some of the disorders through national screening programmes, e.g. 4 million in North America and some 5 million in Western Europe.

Language Selection

Search

Latest News

Newborn Screening - First Steps into the marketplace
Irish technology to enable metabolic disorder screening among newborns in the developing world and remote locations... Read full article on the web Technology…

Read more...

Screen your baby’s health
Enzolve Technologies recently launched a novel newborn screening test for Phenylketonuria (PKU), an inherited metabolic disorder that results in severe mental…

Read more...

UCD campus company to begin production of newborn screening kits for international markets
Enzolve Technologies has recently secured substantial investment from Enterprise Ireland to allow them to begin immediate production of diagnostic screening kits…

Read more...